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ABSTRACT	
  
	
  
Objective: The objective of this selective EBM review is to determine whether or not “Does
Lactobacillus reuteri DSM 17938 reduce daily crying times in infants with colic?”

Study Design: Review of all English language primary studies published in 2010, 2013, 2015.
Data Sources: Three randomized, double blind, placebo controlled clinical trials found using
PubMed.
Outcomes Measured: Daily average crying times were measured by parents who documented
these in a journal.
Results: In all three randomized control studies by Chaeu et al. (2015), Savino et al, (2010), and
Szajewska et al. (2013), they found that infants with colic given Lactobacillus reuteri DSM
17938 had reduced daily crying times as documented by the parents compared to the infants with
colic given a placebo that looked and tasted the same.
Conclusion: All three randomized control trials included in this review indicate that
Lactobacillus reuteri DSM 17938 reduces the daily crying times in infants with colic.
Keywords: infantile colic, Lactobacillus reuteri DSM 17938, reduced cry times.

Kolle,	
  Lactobacillus	
  in	
  infantile	
  colic	
   3	
  
Introduction
Colic is a benign self-limited condition that resolves within a couple of months and has
no standard definition. Clinically, it can be defined by the Wessel’s criteria as crying for no
apparent reason for > 3 hours per day and occurs on > 3 days per week in healthy infants <3
months of age.1 This paper evaluates three randomized, double-blind, placebo- controlled trials
to determine the efficacy of Lactobacillus reuteri DSM 17938 for improving average crying
times for infants with colic.
There are no clearly defined estimates for the prevalence of colic due to provider
differences in diagnostic criteria, populations, and family perceptions. Estimates of the
prevalence of colic in infants range from approximately 8 to 40 percent.1 The exact total
healthcare cost for infantile colic has not been identified either due to the challenges of properly
diagnosing colic.1 Furthermore, it is unknown the exact estimate of healthcare costs to treat colic
due to the differences as well.1
The etiology of infantile colic is unknown; however, it is thought to be due to
gastrointestinal, biologic, and psychosocial reasons. Gastrointestinal reasons include faulty
feeding techniques, cow’s milk protein intolerance, lactose intolerance, gastrointestinal
immaturity, intestinal hypermobility, and alterations in fecal micro flora. Biologic reasons
include immature motor regulation, increased serotonin, maternal smoking during pregnancy and
post-partum, and early form of migraines. Psychosocial reasons include temperament,
hypersensitivity, and parental variables.1
Current treatment methods differ widely. These treatments are mostly trying to control
the infants’ comfort levels and to help with the parents’ quality of life. There is no current cure
for infantile colic. About 80-90% of infants with colic have complete resolving of symptoms by
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four months of age.1 Treatment methods include soothing techniques including pacifiers, taking
the infant for a car ride, rocking, warm baths, and changing feeding techniques. Many parents are
encouraged to also change from milk-based formula to extensive hydrolysate formula, soy
protein formula, lactose-free formula, herbal teas, or fiber-enriched formula. These treatments
have not shown to provide great improvement in the infants’ symptoms. Also, parental support
and education is offered to help the parents care for their child and decrease the stress brought on
by an infant with colic. It is thought that the cause of colic stems from gastrointestinal
disturbances; therefore, the Lactobacillus reuteri DSM 17938 addresses this problem. 1
Objective
The objective of this selective EBM review is to determine whether or not “Does
Lactobacillus reuteri DSM 17938 reduce daily crying times in infants with colic?”
Methods	
  
This	
  investigation	
  looks	
  at	
  three	
  randomized,	
  double	
  blind,	
  placebo	
  controlled	
  
clinical	
  trials.	
  In	
  order	
  to	
  participate	
  in	
  the	
  studies	
  the	
  infants	
  had	
  to	
  be	
  <	
  6	
  months	
  of	
  age	
  
and	
  diagnosed	
  with	
  infantile	
  colic	
  by	
  the	
  Wessel’s	
  criteria.	
  All	
  studies	
  included	
  
Lactobacillus	
  reuteri	
  DSM	
  17938	
  as	
  intervention	
  therapy.	
  In	
  all	
  studies, the comparison
group’s therapy was a placebo identical in appearance and taste. The main outcome looked at for
the purpose of this paper was reduction in average crying times.
The author performed searches using the PubMed databases using the key words of
infantile colic, Lactobacillus reuteri DSM 17938, and reduced cry times. All searches performed
were set for English language. All articles searched were published in peer-reviewed journals
after the year 2010 and were selected based on relevance and importance of outcome to the
patient. Inclusion criteria for the purpose of this paper included randomized, double blind
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controlled studies that included POEMs and exclusively breastfed infants. Exclusion criteria
included previous Cochrane reviews, previous student published systematic reviews, and infants
> 6 months. All studies used similar statistics such as p-value, NNT, RBI, ABI to evaluate the
outcomes. The demographics of the studies are included and outlined below in Table 1.
1. Table 1 - Demographics & Characteristics of included studies

Study

Type

#
Pts

Age
(yrs)

Inclusion Criteria

Exclusion Criteria

W
/D

Interventions

Chau,
2015
(1)

Double
blind
RCT

52

3
weeks6
months

-diagnoses with colic by
Wessel criteria
-age 3 weeks to 6
months
-exclusively breastfed
- term delivery (>37wks)
- 5 minute APGAR
score > 7
-birth weight > 2500 g

-a major medical problem or
acute illness, including gastro
esophageal reflux
-history of ABX tx before or
during the study
- history of probiotic or L
reuteri supplementation
-history of any allergies to any
of the ingredients of the
probiotic
-concurrent participation in
another clinical trial

0

Lactobacillus
reuteri DSM
17938, 5 drops
orally once
daily for 21
days

Savino,
2010
(2)

Double
blind
RCT

50

2-16
weeks

-clinical evidence of chronic
illness or GI disorders
-intake of probiotics and/or
antibiotics in the week
preceding recruitment
-formula feeding
no acid blockers used

4

Lactobacillus
reuteri DSM
17938, 5 drops
orally once
daily, 30
minutes before
feeding, for 21
days

Szajewska,
2013
(3)

Double
blind
RCT

80

16-81
days

- recruited from general
pediatricians and
outpatients at the
Department of
Pediatrics, University of
Turin between March
2008 and August 2009
-exclusively breastfeed
-mothers avoided cow’s
milk in their diet,
-full term infants aged <
5 months
- diagnosed with colic
by Wessel’s criteria
-exclusively or
predominately breastfed

-acute or chronic illness
-gastrointestinal disorders
-use of any ABX and/or
probiotics pharmaceutical
products within 7 days prior
to the study

0

Lactobacillus
reuteri DSM
17938, 5 drops
orally once
daily for 21
days
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Outcomes
All the studies measured the reduction in the duration of average crying and fussing
times. Parents were instructed to keep a diary to record frequency of colic episodes, daily crying
times, feeding schedule, stool frequency, stool characteristics, and any adverse events
experienced.
Results
All three articles reviewed were randomized double blind, placebo controlled studies, and
they all assessed the efficacy of Lactobacillus reuteri DSM 17938 in reducing the crying times of
infants diagnosed with colic. All three used a placebo that was similar in appearance and taste to
the Lactobacillus reuteri DSM 17938. Furthermore, all three studies randomized their sample
population and matched them to the experimental and control groups.
Chau et al. had 55 eligible infants enrolled in the study based on inclusion and exclusion
criteria as in Table 1. There were 27 assigned to receive placebo while 28 were assigned to
receive L. reuteri. They had three participants from the L. reuteri group withdrawn from the trial
and not included in the analysis.2 No adverse reactions were reported in the treatment or placebo
group. At the end of the treatment period (day 21), the L. reuteri group exhibited a significantly
greater reduction in daily crying and fussing time. The average daily crying times for the
treatment group was 60 minutes (IQR 64) compared to the placebo group being 102 minutes
(IQR: 87). P- value was .045, which is statistically significant.2
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Table 2: Primary outcome: duration of crying and/or fussing times in the placebo and L
reuteri DSM 17938 groups
Placebo (n=28)
L reuteri (n=24)
Median
P-value
difference (95%
Cl)
Baseline
122 (163-88)
131 (149-84)
9 (-29 to 46)
.804
Day 7

120 (149-91)

90 (129-53)

-30 (-65 to 5)

.032

Day 14

103 (140-78)

75 (103-54)

-28 (-55 to 0)

.018

Day 21

102 (148-61)

60 (99-35)

-42 (-74 to -10)

.045

Szajewska et al. had 80 infants enrolled in the study based on inclusion and exclusion
criteria as in Table 1. There were 40 infants assigned to receive placebo while 40 were assigned
to receive L. reuteri. There were no participants that were withdrawn. No adverse reactions were
reported in the treatment or placebo group.3 At the end of the treatment period (day 28), the L.
reuteri group exhibited a significantly greater reduction in daily crying and fussing time. The
average daily crying times for the treatment group was 52 minutes (IQR: 30) compared to the
placebo group being 120 minutes (IQR: 38). P- value was <.0001 which is statistically
significant.3
Table 3: Primary outcome: duration of crying and/or fussing times in the placebo and L
reuteri DSM 17938 groups
Probiotic group
(n=40)

Placebo group
(n=40)

P- value

240 (203-278)

Median
difference (95%
Cl)
0.0 (-30 to 30)

Baseline

240 (210-270)

Day 7

180 (149-180)

180 (150-210)

0.0 (-60 to 0)

.002

Day 14

105 (101-120)

150 (120-180)

-45 (-75 to -30)

<.0001

Day 21

75 (60-90)

128 (116-150)

-53 (-83 to -45)

<.0001

Day 28

52 (45-75)

120 (90-128)

-68 (-75 to -60)

<.0001

.8
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Savino et al. had 50 infants in the study based on inclusion and exclusion criteria as Table
1. Four patients were withdrawn from the placebo group analysis due to fever, failure to
complete the diary, or GERD. There were 21 assigned to receive placebo while 25 were assigned
to receive L reuteri.4 There were no withdrawals due to adverse effects related to the trial.
Adverse events reported during the study were rhinitis, eczema, fever, otalgia, and gastro
esophageal reflux. At the end of the treatment period (day 21), the L reuteri group exhibited a
significantly greater reduction in daily crying and fussing time. The average daily crying times
for the treatment group was 35 minutes (IQR: 85) compared to the placebo group being 90
minutes (IQR: 148). P- value was .022 which is statistically significant.4
Table 4: Primary outcome: duration of crying and/or fussing times in the placebo and L
reuteri DSM 17938 groups
L reuteri group
Placebo group (n=21), P- value
(n=25), Median (IQR) Median (IQR)
Baseline
370 (120)
300 (150)
.127
Day 7

95 (85)

185 (149)

.082

Day 14

60 (70)

150 (145)

.099

Day 21

35 (85)

90(148)

.022

Discussion
All studies were very similar in patient population, sample size, inclusion criteria,
exclusion criteria, sample size, methods, and results. They all had the same general outcomes as
well. The only difference is Savino et al addresses bacteria in the stools. They took stool samples
throughout the trial to evaluate the bacteria concentrations such as E. coli.4
Currently, Lactobacillus is mostly offered over the counter for infants and children. It is
available as drops, capsules, caplets, granules, powder, tablets, chewable tablets, and wafers. It is
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also available as an intramuscular injection.5 Gerber Soothe colic drops, which are L. reuteri
drops, cost about $24.99 on average.6 These drops are marketed to help improve good bacteria in
an infant’s digestive system, which helps to promote digestive comfort. Parents have complained
of excess flatulence and bloating while the infant is taking these probiotic drops. It is
recommended to use caution with patients who are immunocompromised because it is a live
bacterium. Because probiotics are classified as dietary supplements, there are no safety reviews
and approved indications by the FDA. Furthermore, there are currently no black box warnings
or known drug interactions.5
One limitation for these studies was sample size. The sample sizes were 50, 52, and
80.2,3,4 Another limitation was the parents’ accuracy in documenting the daily average crying
times, and all the studies discussed this limitation. The parents’ perceptions of the crying times
vary, and the time that the parents document the crying times could change the accuracy of the
crying times documented. One study was concerned parents would wait until the day of the
infant’s appointment to document all the crying times.3 Compliance was also not assessed in two
studies. It is hard to definitely classify crying times when it is based on many different parents’
perceptions versus crying times determined by a single person.
Conclusion
After reviewing these three studies, evidence strongly suggests that Lactobacillus reuteri
DSM 17938 does reduce daily crying times in infants with colic. The studies followed the
participants for an appropriate amount of time, and although the sample sizes were relatively
smaller in each study, the results found were still considered statistically significant. The
limitation with these studies is there was no objective way to measure crying times. The studies
had to rely on the parents to document the crying times daily in a diary. One way to fix this
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limitation would be to have voice-activated recorders to measure the crying times. One area of
thought for further research about infantile colic was discussed by Savino et al. They checked
stool samples. They determined that there was an increase in the probiotic in the stool and a
decrease in E.coli.2 E. coli has been found to be in higher concentrations in the stool of those
infants with colic than those infants without colic.2 There should be a further study to determine
if E. coli decreasing in the stool decreases the crying times in the infants as well. This would also
provide a more objective way to determine if infantile colic is due to gastrointestinal symptoms.
Also, future study is warranted to determine if infantile colic predisposes infants to have
recurrent abdominal pain, allergic diseases, or psychological disorders later in life. This study
could be used to determine if probiotics are recommended to these infants later in life as well.
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